Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period

Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, Kunz PL, Grande E, Valle JW, Dillon JS, Lapuerta P, Banks P, Jackson S, Pavel ME (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Pancreas Lippincott, Williams & Wilkins

Book Volume: 47

Pages Range: 341-342

Journal Issue: 3

DOI: 10.1093/annonc/mdx368.012

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

University of Iowa

United States (USA) (US) UCSF Helen Diller Family Comprehensive Cancer Center

United States (USA) (US) Stanford University

United States (USA) (US) Zentralklinikum Bad Berka

Germany (DE) Dana–Farber Cancer Institute

United States (USA) (US) Hospital Universitario Ramón y Cajal

Spain (ES) Lexicon Pharmaceuticals, Inc.

United States (USA) (US) Icahn School of Medicine at Mount Sinai

United States (USA) (US) Uppsala University

Sweden (SE) University of Manchester

United Kingdom (GB) Royal Free Hospital

United Kingdom (GB) University of Kentucky

United States (USA) (US)

How to cite

APA:

Hoersch, D., Kulke, M.H., Caplin, M.E., Anthony, L.B., Bergsland, E., Oberg, K.,... Pavel, M.E. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. (pp. 341-342).

MLA:

Hoersch, Dieter, et al. "Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period." 2018. 341-342.

BibTeX: Download